Cross-reactive serum IgG antibodies against non-vaccine VLP elicited by rNV-2v
Kawasaki
REGRESSION, KAWASAKI
The rNV-2v vaccine elicited cross-reactive IgG antibodies against non-vaccine VLPs. The cross-reactive IgG titers of anti-GI.3 (2002), anti-GII.4 (1999), anti-GII.4 Sydney (2012), and anti-GII.17 Kawasaki 308 (2015) have already been reported by Leroux-Roels et al. (Cross-reactive anti-GII.2, anti-GII.4, and anti-GII.6 VLP IgG responses. Cross-reactive IgG responses against the non-vaccine strain VLP at the scheduled time for each treatment. Vaccine or placebo were administered on days 1 and 29. The cross-reactive IgG arbitrary response unit (ARU) is defined as the reciprocal of the dilution factor or c value (inflection point) of the 4-parameter logistic regression equation. Anti-GII.2 OC08154 (2008) Evolutionary relationships of VP1 protruding domains of norovirus VLPs used in ELISA assays to assess cross-reactive IgG and respective fold-change graphs. In Antibody response to non-vaccine antigens expressed as Geometric Mean of arbitrary response units (ARU) of anti-GII.2, anti-GII.4, and anti-GII.6 VLP IgG at scheduled time points for each study group.CI, confidence interval; Geomean, geometric mean antibody concentration.*Geometric mean values are expressed as arbitrary response units (ARU) deﬁned as the reciprocal of the dilution factor or c value (inflection point).Antibody response to vaccine and non-vaccine antigens expressed as median of fold increase from baseline (day 1) for anti-VLP IgG at scheduled time points for each study group.For GII.2 OC08154 (2008) and GII.4 Washington (2018), the IgG titers were evaluated at pre-vaccination (day 1), day 8, day 29 (before the second vaccination), and on day 57. Cross-reactive IgG titers increased after the first vaccination but did not rise further after the second vaccination in both rNV-2v groups (The evolutionary relationships of the VP1 protruding domains of norovirus VLPs used in ELISA assays to assess cross-reactive IgG are illustrated in 